Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous ...
Mar 11, 2026 · Apixaban and rivaroxaban are the oral anticoagulants most frequently used to treat acute venous thromboembolism. However, uncertainty remains about the difference in bleeding risk …
The New England Journal of Medicine | Research & Review Articles on ...
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of ...
Romiplostim versus Placebo for Chemotherapy-Induced …
Mar 11, 2026 · Chemotherapy-induced thrombocytopenia (CIT) is a common complication of chemotherapy that is associated with bleeding, reduced relative dose intensity, and potentially worse …
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer
Feb 18, 2026 · Patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy proceed directly to radical cystectomy with pelvic lymph-node dissection. …
Recently Published | The New England Journal of Medicine
6 days ago · Explore this issue of The New England Journal of Medicine (Vol. 0 No. 0).
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple …
Dec 9, 2025 · In a phase 1–2 trial, teclistamab, a bispecific antibody targeting CD3 on T-cell surfaces and B-cell maturation antigen on myeloma cells, showed durable responses in heavily pretreated …
Medical Management and Revascularization for Asymptomatic Carotid ...
Nov 21, 2025 · Improvements in medical therapy, carotid-artery stenting, and carotid endarterectomy call into question the preferred management of asymptomatic carotid stenosis. Whether adding …
One Pivotal Trial, the New Default Option for FDA Approval — Ending …
Feb 18, 2026 · This Sounding Board announces a new FDA policy that the default requirement for FDA approvals will be one robust pivotal trial plus confirmatory evidence, rather than two trials.
Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced ...
Jan 28, 2026 · The current standard first-line treatment for hormone-receptor–positive, HER2-positive metastatic breast cancer consists of induction chemotherapy, combined with trastuzumab and …
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated ...
Apr 30, 2025 · Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction–associated steatohepatitis (MASH). In this ongoing phase 3, multicenter ...